A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

In this phase II study, 39 women (median age 51 years) with advanced breast cancer received docetaxel (75 mg m-2) intravenously over 1 h every 3 weeks as first-line chemotherapy for advanced disease, without routine premedication for hypersensitivity reactions. In 31 evaluable patients, an overall r...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P., Fumoleau, P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074661/
https://www.ncbi.nlm.nih.gov/pubmed/8761385

Ejemplares similares

Ejemplares similares